William Lewis

William Lewis, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in INSMED Inc and NewAmsterdam Pharma Co N.V. Over a trading history stretching from 1 February 2016 to 23 July 2026, the count stands at 85 filings.

In open-market terms, that means 1 purchase on one side and 30 sales worth €9.6M on the other. The totals do not cover 6 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 12 share grants and 42 option exercises. Since January 2026: no purchases and 20 sales on the market.

The record was last updated on 24 July 2026 with an open-market sale (€446k) in INSMED Inc. The most recent open-market purchase was published on 3 February 2016, 3,910 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.